<DOC>
	<DOCNO>NCT00721409</DOCNO>
	<brief_summary>The study aim confirm letrozole + PD 0332991 safe tolerable ass effect combination advance breast cancer</brief_summary>
	<brief_title>Study Of Letrozole With Or Without Palbociclib ( PD-0332991 ) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inoperable estrogen receptor positive HER2 negative breast cancer . Postmenopausal status . Tumor tissue ( archive acceptable ) available biomarker study . For Phase 2 Part 2 CCND1 amplification and/or loss p16 determine central laboratory . Acceptable bone marrow , liver kidney function . Prior concomitant treatment advance breast cancer . Other major cancer past 3 year . Important cardiovascular event past 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hormone-receptor positive advance breast cancer</keyword>
</DOC>